/
BCDA
$1.21+$0.01 (+0.83%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$17.9M
15M shares
52-week range
$0.78 – $2.45
26% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Borrow rate
44.25%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-57.44
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $625.0K | $710.0K | $145.0K | $1.0M | $1.4M | $477.0K | $58.0K | $0 |
| Cost of revenue | $517.0K | $358.0K | $4.0K | $640.0K | $8.8M | $7.7M | $4.4M | $505.0K |
| Gross profit | $108.0K | $352.0K | $141.0K | $375.0K | −$7.5M | −$7.2M | −$4.3M | −$505.0K |
| Gross margin | 17.3% | 49.6% | 97.2% | 36.9% | -553.4% | -1519.7% | -7463.8% | — |
| R&D | $8.5M | $8.6M | $9.8M | $8.6M | $8.8M | $7.7M | $4.4M | $5.0M |
| Operating income | −$14.1M | −$14.2M | −$15.5M | −$12.6M | −$11.9M | −$11.6M | −$8.0M | −$8.3M |
| EBITDA | −$13.9M | −$14.0M | −$14.4M | −$12.6M | −$11.8M | −$11.5M | −$7.9M | −$7.7M |
| Net income | −$14.0M | −$14.7M | −$15.0M | −$12.6M | −$11.9M | −$11.6M | −$7.9M | −$8.2M |
| Net margin | -2237.9% | -2071.7% | -10347.6% | -1243.4% | -880.7% | -2425.8% | -13700.0% | — |
| EPS (diluted) | -48.80 | -39.15 | -22.20 | -11.19 | -10.05 | -8.19 | -2.90 | -1.23 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $50000 | $-0.68 | $-0.68–$-0.68 | 1 |
| 2027 | $50000 | $-0.53 | $-0.53–$-0.53 | 1 |
| 2028 | $4M | $-0.41 | $-0.42–$-0.40 | 2 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$0.21
Price
$1.21
Implied downside
-83%
Peer comparison
BioCardia, Inc. Common Stock
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
www.biocardia.com- Employees
- 21
- IPO / List date
- Oct 25, 1995
- HQ
- SUNNYVALE, CA
Held by traders on TradeandTell
No one on the platform currently holds BCDA.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 13,900 | $16.8K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2024-05-30 | 1-for-15reverse |
| 2019-06-06 | 1-for-9reverse |
| 2017-11-03 | 1-for-12reverse |
| 2004-01-06 | 6-for-1 |
Recent trades on TradeandTell
No one on the platform has traded BCDA yet.
